Ensysce Biosciences Announces Successful Completion of Clinical Study for Pain Medication with Overdose Protection, Amgen and TScan Therapeutics Collaborate to Identify Antigens for Crohn's Disease Treatment
- May 09th, 2023
- 410 views
Ensysce Biosciences, Inc. (Nasdaq: ENSC) has completed the clinical study of its first pain medication with overdose protection, PF614-MPAR, known as PF614-MPAR-101. The final Part B of the study showed that PF614-MPAR effectively reduced opioid delivery when three or more doses were consumed simultaneously, with dose escalation from 25 to 200 mg (1 to 8 dose units).
In other news, Amgen (Nasdaq: AMGN) and TScan Therapeutics, Inc. (Nasdaq: TCRX) have announced a collaboration to identify antigens recognized by T cells in Crohn's disease patients. TScan will receive a $30 million upfront payment and may receive over $500 million in success-based preclinical, clinical, regulatory and commercial milestones. Additionally, tiered single-digit royalty payments will be made.
$ENSC is trading at $5.96, up by 73.33% or $2.52. Meanwhile, $TCRX is trading at $4.25, up by 97.67% or $2.10.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
A Preview: Oracle, Franco-Nevada, and Asana Earnings Due
March 09th, 2025NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025
Member Login